Gilead offers its newest HIV drug candidate to patent pool for low-cost production
admin 4th October 2017 Uncategorised 0Gilead Sciences is licensing its newest HIV drug candidate, bictegravir, to the U.N.-backed Medicines Patent Pool, meaning it will be produced and sold at a lower cost in 116 low- and middle-income countries once it is approved.
More: Gilead offers its newest HIV drug candidate to patent pool for low-cost production
Source: fierce